# A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient

> **NCT07649395** · NA · COMPLETED · sponsor: **Mei Feng** · enrollment: 75 (actual)

## Conditions studied

- Cervical Squamous Cell Carcinoma

## Interventions

- **DRUG:** rhTPO
- **DRUG:** rhTPO

## Key facts

- **NCT ID:** NCT07649395
- **Lead sponsor:** Mei Feng
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649395, "A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*